The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

Tuberkuloz ve Toraks (Tuberculosis and Thorax) is a distinguished journal published by the TURKISH ASSOCIATION OF TUBERCULOSIS AND THORAX located in Turkey. Serving as a pivotal platform for researchers and practitioners in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, this journal has been disseminating vital research since 2003 and is committed to advancing knowledge and clinical practices related to tuberculosis and thoracic diseases. Although currently not an Open Access publication, its relevance is underscored by its rankings within Scopus, including a Q3 category in Critical Care and Intensive Care Medicine and a Q4 in Pulmonary and Respiratory Medicine, reflecting its significant contributions to the academic community. With a mission to foster the exchange of innovative ideas and encourage rigorous scholarly discourse, Tuberkuloz ve Toraks plays an essential role in addressing pressing health challenges associated with respiratory ailments and remains an invaluable resource for researchers, health professionals, and students dedicated to improving outcomes in thoracic health.

Welcome to the Canadian Journal of Respiratory Critical Care and Sleep Medicine, a prestigious peer-reviewed journal published by Taylor & Francis Inc. With an ISSN of 2474-5332 and an E-ISSN of 2474-5340, this journal serves as a vital platform for disseminating cutting-edge research in the fields of critical care, intensive care medicine, and pulmonary and respiratory medicine. Since its inception in 2017, the journal has established itself within the academic community, currently holding a Q2 ranking in Critical Care and Intensive Care Medicine and a Q3 ranking in Pulmonary and Respiratory Medicine for 2023. Although it operates under a standard access model, the journal remains committed to providing valuable insights and advancing knowledge through rigorous research articles, reviews, and case studies. Positioned in the heart of the United States, the journal aims to foster collaboration and innovation among healthcare professionals, researchers, and students dedicated to enhancing respiratory care and critical treatment protocols. Join us in exploring the dynamic intersection of research and practice that defines our mission.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Annals of the American Thoracic Society is a premier journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by the American Thoracic Society, this journal offers an invaluable platform for researchers and clinicians to disseminate cutting-edge research, clinical insights, and innovative methodologies. With an impressive impact factor and ranked in the top Q1 category of its field (2023) and within the top 20 of 155 according to Scopus rankings, it is positioned as a leading force in shaping clinical practice and research directions. The journal's convergence years from 2013 to 2024 indicate a commitment to providing timely and relevant content at the forefront of pulmonary health. While not an open-access journal, it ensures broad accessibility to its significant contributions in respiratory medicine, making it an essential resource for professionals, researchers, and students alike endeavoring to deepen their understanding and improve outcomes in thoracic health.

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

Jornal Brasileiro de Pneumologia is a pivotal open-access journal in the field of Pulmonary and Respiratory Medicine, published by SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA. Established in 2004, this esteemed publication has become a significant platform for researchers, health professionals, and students in Brazil and beyond, facilitating the exchange of innovative ideas and vital research findings. The journal is indexed in Scopus and is recognized in the 2023 category quartiles as Q3, ranking 86 out of 155 in its field with a corresponding 44th percentile. This reflects its growing influence and commitment to advancing knowledge concerning respiratory health. With a mission to disseminate high-quality research, the journal aims to foster advancements in clinical practice and improve outcomes in pulmonary diseases, making it an essential resource for those dedicated to enhancing the quality of care in respiratory medicine. For those seeking comprehensive access to critical studies and reviews in this domain, the Jornal Brasileiro de Pneumologia remains an invaluable asset.

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.